AARON Eine offene Phase-II-Studie von Relatlimab (BMS-986016) mit Nivolumab (BMS-936558) in Kombination mit 5-Azacytidin zur Behandlung von Patienten mit refraktärer/rezidivierter akuter myeloischer Leukämie und neu diagnostizierten älteren Patienten mit akuter myeloischer Leukämie (Aktiv)
AML BFM Registry 2017 AML BFM Registry 2017: Klinisches Register für Kinder und Jugendliche mit akuter myeloischer Leukämie (Aktiv)
AML-BMF 2020 International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents (Aktiv)
CHDM201H12101C HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (Aktiv)
HaploMUDStudy Phase II Studie zu Spendertypen für die allogene Stammzelltransplantation bei akuter Leukämie (Aktiv)
Janssen 75276617ALE1002 A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (Aktiv)
ML DS 2018 Phase II/III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018 (Aktiv)
NIFAR Phase 1/2 trial to test Nivolumab in treatment failure of Acute Myeloid Leukemia (AML) after stem cell transplantation by a allogenic donor (allo-SCT) (Aktiv)
PALOMA Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA) (Aktiv)
PEMAZA MRD-guided Treatment in NPM1mut AML Patients (PEMAZA) (Aktiv)
SAL-AML Register AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) (Aktiv)
TUD-APOLLO-064 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) (Aktiv)
Erstlinie
AMLSG 21-13 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) (Aktiv)
AMLSG 24-15 Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 (Aktiv)
AMLSG 29-18 / HOVON 150 A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (Aktiv)
AMLSG 30-18 Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics (Aktiv)
AMLSG 31-19 / HOVON 501 Eine randomisierte, placebokontrollierte Phase-III-Studie zur Induktions- und Konsolidierungs-Chemotherapie mit Venetoclax bei erwachsenen Patienten mit neu diagnostizierter akuter myeloischer Leukämie oder myelodysplastischem Syndrom mit Blastenüberschuss-2 (Aktiv)
CPKC412A2218-Midostaurin_FLT3-AML A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML (Aktiv)
DECIDER-2_AMLSG 32-21 Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy (Aktiv)
DaunoDouble Randomisierter Vergleicher zwischen zwei Dosierungen von Daunorubicin und zwischen Einfach- und Doppel-Induktionstherapie bei erwachsenen Patienten mit Akuter Myeloischer Leukämie ≤ 60 Jahre (Aktiv)
MOSAIC Addition of midostaurin and gemtuzumab ozogamicin to standard chemotherapy with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia (Aktiv)
NAPOLEON National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup (Aktiv)
STIMULUS-AML1 (CMBG453C12201) A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy (Aktiv)
TUD-VINC01-080 Venetoclax Plus Azacitidine Versus Standard Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations Eligible for Intensive Treatment (Aktiv)
VENAZA-5S A Single-arm, Pilot Study of Venetoclax in Combination With 5 Days Azacitidine in Treatment-naïve Subjects With Acute Myelogenous Leukemia Who Are ≥18 Years of Age and Not Eligible for Standard Induction Therapy (VENAZA-5S PILOT TRIAL) (Aktiv)
WINK (SMS-0341_WiNK) A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia (Aktiv)
Zweitlinie oder später
AMG 330 A Phase 1 First-in-human Study Evaluating AMG 330 Administered as Continuous Intravenous Infusion (Aktiv)
AMLSG26-16/AML-VIVA Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML (AML-ViVA) (Aktiv)
Avencell AVC-201-01 Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T cells Carrying Reverse Chimeric Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123. (Aktiv)
DOSE ESCALATION OF RO7283420 IN AML EINE OFFENE, MULTIZENTRISCHE PHASE-I-STUDIE ZUR BEURTEILUNG DER SICHERHEIT, VERTRÄGLICHKEIT, PHARMAKOKINETIK UND PHARMAKODYNAMIK VON RO7283420 ALS EINZELWIRKSTOFF BEI HÄMATOLOGISCH UND MOLEKULAR REZIDIVIERTER/REFRAKTÄRER AKUTER MYELOISCHER LEUKÄMIE (Aktiv)
H3 Biomedicine Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (Aktiv)
MOLIVO-1 (AMLSG 33-22) Phase-Ia/IIb-Studie mit PHD-Inhibitor Molidustat in Kombination mit IDH1-Inhibitor Ivosidenib bei Patienten mit IDH1-mutierter rezidivierter/refraktärer AML oder MDS/AML (Aktiv)
PONS Ponatinib for Treatment of Patients with CP-CML after treatment with other TKI has failed (Aktiv)
RELAX (AML) Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (Aktiv)
UC02-123-01 Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies (Aktiv)